Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
117
-
Total 13F shares, excl. options
-
113M
-
Shares change
-
-5.61M
-
Total reported value, excl. options
-
$105M
-
Value change
-
-$4.22M
-
Put/Call ratio
-
0.03
-
Number of buys
-
35
-
Number of sells
-
-61
-
Price
-
$0.93
Significant Holders of Nektar Therapeutics - Common Stock, par value $0.0001 per share (NKTR) as of Q1 2024
137 filings reported holding NKTR - Nektar Therapeutics - Common Stock, par value $0.0001 per share as of Q1 2024.
Nektar Therapeutics - Common Stock, par value $0.0001 per share (NKTR) has 117 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 113M shares
.
Largest 10 shareholders include Deep Track Capital, LP (18.4M shares), VANGUARD GROUP INC (12M shares), ACADIAN ASSET MANAGEMENT LLC (7.57M shares), PRIMECAP MANAGEMENT CO/CA/ (6.97M shares), BlackRock Inc. (5.88M shares), Monaco Asset Management SAM (5.83M shares), RENAISSANCE TECHNOLOGIES LLC (4.62M shares), TCG Crossover Management, LLC (4M shares), Stonepine Capital Management, LLC (3.48M shares), and CITADEL ADVISORS LLC (3.19M shares).
This table shows the top 117 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.